Christine Greco

Dr. Christine Greco

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in Pediatric Critical Care Medicine
Verified
Journal Article
Closed access
JSJean C Solodiuk
Jean C Solodiuk
CDCarolina Md Donado
Carolina Md Donado
LWLia Msn Wickerham
Lia Msn Wickerham
LGLindsay Msn Goodyear
Lindsay Msn Goodyear
JHJohn Rn Hayes
John Rn Hayes
MCMartha A. Q. RN Curley
Martha A. Q. RN Curley
OBJECTIVES: To develop and conduct preliminary testing of the Withdrawal Assessment Tool-Alpha 2 Agonist (WAT-A2A) to monitor dexmedetomidine and clonidine withdrawal symptoms in acutely ill children. DESIGN: Three-phase instrument development study. Phase 1: retrospective chart review of symptoms exhibited by children with documented dexmedetomidine withdrawal; phase 2: WAT-A2A instrument construction based on phase 1 data; and phase 3: prospective testing of the WAT-A2A in children weaning from alpha 2 agonists (A2As). SETTING: Academic free-standing children’s hospital. PATIENTS: Acutely ill children weaning from at least 5 days of dexmedetomidine. Excluded were children concurrently weaning other sedatives. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Phase 1: In 83 of 303 children weaning from at least 5 days of dexmedetomidine who had clinician documentation and were managed for A2A withdrawal, 88% (n = 72) exhibited at least a 20% increase in heart rate (HR), 83% (n = 69) exhibited agitation or change in usual state behavior, 46% (n = 38) exhibited at least a 20% increase in diastolic blood pressure (DBP), and when documented, 56% (27/48) exhibited tremors during their A2A withdrawal episode. Phase 2: The WAT-A2A was constructed, based on phase 1 data, and includes four items: HR, state behavior, DBP, and tremors. Phase 3: The WAT-A2A was tested and performed well in 82 children weaning from A2A. The total WAT-A2A score correlated with clinician subjective assessment of A2A withdrawal (Spearman correlation = 0.5; p < 0.001). Inter-rater agreement, comparing paired ratings of prospectively collected WAT-A2A data, indicated moderate inter-rater reliability. CONCLUSIONS: Acutely ill children receiving sedation with an A2A for more than 5 days may develop physiologic dependence, requiring gradual dosing reductions. While further psychometric testing is advised, the WAT-A2A provides an objective instrument to help clinicians quantify dexmedetomidine withdrawal symptoms in acutely ill children may facilitate A2A weaning and limit unnecessary variation in practice.

11 January 2023 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
CDCarolina Donado
Carolina Donado
EHEmily M. Harris
Emily M. Harris
MHMatthew Heeney
Matthew Heeney
JSJean C. Solodiuk
Jean C. Solodiuk
CGChristine Greco
Christine Greco
NANatasha M. Archer
Natasha M. Archer

10 March 2026 in Children
Verified
Journal Article
Open access
PDF file
JDJoseph DeBettencourt
Joseph DeBettencourt
MNMatthew Nagy
Matthew Nagy
CRChloe Rotman
Chloe Rotman
CGChristine Greco
Christine Greco
CBCharles Berde
Charles Berde
NANatasha M. Archer
Natasha M. Archer
Background and Objective: Sickle cell disease (SCD) is an inherited blood disorder associated with recurrent painful crises. Sickle cell pain crises are a significant source of distress for patients and contribute substantially to hospital utilization among SCD populations. Many children with SCD also experience chronic pain, which is often multifactorial in nature. The management of both acute and chronic pain in SCD commonly relies on opioid medications. Acute and chronic use of opioids is associated with health risks and potential complications, which has raised interest in alternatives. Buprenorphine is a partial μ-receptor agonist with strong affinity that confers pain relief and may have an improved side-effect profile. While there is emerging evidence for its use in adult patients, the data is less developed in pediatrics. Methods: A scoping review was designed in accordance with PRISMA guidelines to systematically explore the literature on buprenorphine use in pain management for children with sickle cell disease (SCD). Results: This review shows that the published literature in this area is of low quality and extremely limited, and there is a lack of trials specifically designed to address the use of buprenorphine for this patient population. Studies are limited in their generalizability but suggest that buprenorphine may be useful in managing pain in this population. Conclusions: While promising, more data is required both retrospectively and prospectively to understand the utility of buprenorphine. The development of pediatric-specific protocols for transitioning from full µ-receptor agonist opioids to buprenorphine is also needed.

22 February 2020
Verified
Book Chapter
Closed access
PDF file
CGChristine Greco
Christine Greco
NSNavil F. Sethna
Navil F. Sethna

9 March 2026 in The Clinical Journal of Pain
Verified
Journal Article
Open access
LRLeah PsyD Reece
Leah PsyD Reece
MMMorgan Bs Mitcheson
Morgan Bs Mitcheson
CDCarolina Md Donado
Carolina Md Donado
JSJulie Shulman
Julie Shulman
MRMonique Ribeiro
Monique Ribeiro
CGChristine Greco
Christine Greco
Context: Chronic pain affects 1 in 9 young adults worldwide. Intensive interdisciplinary pain treatment (IIPT) has shown favorable outcomes in improving in pain intensity, mood, school attendance, and social and physical functioning in pediatric studies. However, few IIPT programs are designed for young adults (YAs), a distinctly vulnerable developmental stage. Given this limitation, we sought to study the benefits of applying an IIPT model for YAs with chronic pain and functional impairment. Objectives: This study aimed to (1) describe the design and implementation of our pilot YA-IIPT program and (2) assess outcomes of YA-IIPT on pain experience, psychological and physical functioning, disability, and quality of life, in YAs with chronic pain and functional impairment. Methods: In this observational study, we adapted the pediatric IIPT model for YAs using a biopsychosocial approach to chronic pain treatment. Outcome measures included physical functioning, psychological functioning, disability, quality of life, and pain experience. Paired t tests and repeated-measure ANOVAs were used to compare admission, discharge, 6-week, and 6-month follow-up data. Results: Patients showed clinically and statistically significant improvements across the majority of physical and psychological functioning, disability, quality of life, and pain experience measures between admission and discharge ( P <0.01). Most improvements were maintained at 6-week and 6-month follow-ups. Discussion: On average, participants in our YA-IIPT program demonstrated clinically and statistically significant improvements in most areas of functioning, quality of life, and pain experience that were maintained after discharge. Further research is needed on YA pain treatment and whether outcomes after YA-IIPT are sustained long-term.

18 September 2026 in Drug and Alcohol Dependence Reports
Verified
Journal Article
Open access
CKCamila Koike
Camila Koike
NTNicole Tacugue
Nicole Tacugue
ESErin Sands
Erin Sands
EWElissa R. Weitzman
Elissa R. Weitzman
CGChristine Greco
Christine Greco
JKJoe Kossowsky
Joe Kossowsky